TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29017627
Drug: 40 g
Normalized name: PEG-40 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g mycoprotein (MYC40)
Study: 29017627
Drug: 60 g
Normalized name: aspirin 60 Grains
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 g mycoprotein (MYC60)
Study: 29017627
Drug: 80 g
Normalized name: PEG-80 GLYCERYL COCOATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 g mycoprotein (MYC80)
Study: 25622774
Drug: Ticagrelor (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor (180 mg loading, 90 mg twice daily for maintenance dose)
Study: 25622774
Drug: Clopidogrel (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (300 mg loading, 75 mg once daily for maintenance dose)
Study: 23179117
Drug: Ropivacaine 0.25%
Normalized name: ROPivacaine 0.25%-NaCl 0.9% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.25% with 20 mg parecoxib locally on the nerve block (Group B)
Study: 23179117
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg parecoxib intravenously (Group C)
Study: 21351829
Drug: Maximal doses
Normalized name: Spirulina maxima preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maximal doses of 20 Gy delivered by the X‐knife unit 16 days postimplantation
Study: 15560538
Drug: Bisoprolol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol (5 mg daily)
Study: 8367518
Drug: Model based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Model based on renography parameters (excretion ratio, rate of uptake, time to peak activity)
Study: 6761832
Drug: Flunisolide 50
Normalized name: Flunisolide
DrugBank: Flunisolide acetate (DB14662)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flunisolide 50 micrograms in each nostril twice daily
Study: 6761832
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate 50 micrograms in each nostril four times daily
Study: 28454194
Drug: Operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative treatment (arthroscopy of the shoulder)
Study: 28454194
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (physiotherapy under physician control)
Study: 25875938
Drug: Laughter therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laughter therapy (3 sessions, 60 minutes each)
Study: 19204263
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) 20 mg p.o. with interferon beta‐1a
Study: 19204263
Drug: IV methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV methylprednisolone (IVMP) 1,000 mg/day for 3 days bimonthly with interferon beta‐1a
Study: 23666772
Drug: Acceptance-based behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance-based behavioral treatment (ABT)
Study: 25743263
Drug: Pasireotide (600-1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide (600-1200 µg bid for at least 6 months)
Study: 21696245
Drug: Lipid-based nutrient
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-based nutrient supplement (LNS), a peanut-based micronutrient fortified paste
Study: 19783896
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of atorvastatin plus 10 mg of ezetimibe
Study: 19783896
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of atorvastatin plus 10 mg of ezetimibe (after crossover)
Study: 19783896
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg of atorvastatin (initially)
Study: 16432273
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba (Ginkgold, 3 doses of 120 mg)
Study: 9432291
Drug: Fluvastatin (Lescol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin (Lescol, Sandoz Pharma Ltd) 20 mg once daily, increased to 40 mg if LDL‐Ch > 3.5 mmol/l
Study: 1528206
Drug: Caffeine (equal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (equal to daily caffeine consumption)
Study: 29777823
Drug: Atezolizumab, 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab, 1200 mg, intravenously every 3 weeks
Study: 29777823
Drug: Docetaxel, 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel, 75 mg/m2, intravenously every 3 weeks
Study: 27105870
Drug: EPA-rich triglyceride
Normalized name: CAPRYLIC TRIGLYCERIDE
DrugBank: Tricaprylin (DB12176)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA-rich triglyceride concentrates (3.1 g EPA/d)
Study: 27105870
Drug: DHA-rich triglyceride
Normalized name: CAPRYLIC TRIGLYCERIDE
DrugBank: Tricaprylin (DB12176)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA-rich triglyceride concentrates (2.9 g DHA/d)
Study: 25295645
Drug: MDX 1400
Normalized name: hydrocortisone acetate Topical Gel [Cortisil MDX]
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDX 1400 mg
Study: 25295645
Drug: MDX 700
Normalized name: hydrocortisone acetate Topical Gel [Cortisil MDX]
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDX 700 mg
Study: 22537617
Drug: VEGF Trap-Eye
Normalized name: Trapa bicornis seed extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: VEGF Trap-Eye 0.5 mg every 4 weeks (0.5q4)
Study: 22537617
Drug: VEGF Trap-Eye
Normalized name: Trapa bicornis seed extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: VEGF Trap-Eye 2 mg every 4 weeks (2q4)
Study: 22537617
Drug: VEGF Trap-Eye
Normalized name: Trapa bicornis seed extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: VEGF Trap-Eye 2 mg every 8 weeks after 3 initial monthly doses (2q8)
Study: 22537617
Drug: VEGF Trap-Eye
Normalized name: Trapa bicornis seed extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: VEGF Trap-Eye 2 mg as needed after 3 initial monthly doses (2PRN)
Study: 16213930
Drug: Azithromycin (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (12 mg/kg on days 1-5, repeated on days 11-15 and days 21-25)
Study: 16213930
Drug: Placebo (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (administered in the same regimen for a 30-day period)
Study: 9658884
Drug: Cisplatin 80
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 80 mg/m2 day 1 and etoposide 120 mg/m2 on days 1-3, with vinblastine 5 mg/m2 on days 1 and 3 (in 58 patients)
Study: 9658884
Drug: Cisplatin 80
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 80 mg/m2 day 1 and etoposide 120 mg/m2 on days 1-3 (without vinblastine)
Study: 9658884
Drug: Cisplatin and
Normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin and etoposide treatment
Study: 7846096
Drug: Iron fortification
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron fortification (soup fortified with 20 mg iron and 100 mg vitamin C for 15 weeks on school days)
Study: 3229833
Drug: Plaster treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plaster treatment
Study: 28579168
Drug: Drug-coated stent
Normalized name: castor fiber scent gland secretion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-coated stent (DCS)
Study: 23890742
Drug: Gel alcohol-based
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gel alcohol-based hand rub (ABHR) formulations
Study: 23890742
Drug: Liquid alcohol-based
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liquid alcohol-based hand rub (ABHR) formulations
Study: 21205043
Drug: Nicotine nasal
Normalized name: nicotine Nasal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine nasal spray (NNS) for 12 weeks
Study: 18461848
Drug: Hanen Parent
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hanen Parent Program (experimental treatment group)
Study: 16476889
Drug: Retinal ablation
Normalized name: retinaldehyde
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retinal ablation treatment for severe acute-phase ROP
Study: 2839280
Drug: No antitumor
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antitumor therapy
Study: 25975423
Drug: Etravirine 200
Normalized name: etravirine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etravirine 200 mg twice daily + Telaprevir 750 mg every 8 hours
Study: 25975423
Drug: Rilpivirine 25
Normalized name: rilpivirine 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilpivirine 25 mg once daily + Telaprevir 750 mg every 8 hours
Study: 16181539
Drug: Safflower Yellow
Normalized name: SAFFLOWER
DrugBank: Safflower (DB10905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safflower Yellow injection (SYI)
Study: 16181539
Drug: Salvia injection
Normalized name: SALVIA OFFICINALIS
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salvia injection (Control)
Study: 14625518
Drug: Ice treatment
Normalized name: Lice Treatment
DrugBank: Pyrethrum extract (DB11087)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ice treatment with light shoulder exercise (ILSE)
Study: 14625518
Drug: Ice treatment
Normalized name: Lice Treatment
DrugBank: Pyrethrum extract (DB11087)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ice treatment (IT)
Study: 10507602
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Se-), received 35 microg of sodium selenite throughout the treatment period.
Study: 7158232
Drug: Oestradiol-17 beta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oestradiol-17 beta orally (2-4 mg)
Study: 7158232
Drug: Oestradiol-17 beta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oestradiol-17 beta cutaneously (3 mg)
Study: 24760484
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine (TCM)
Study: 25832312
Drug: CZP 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: CZP 200 mg every 2 weeks
Study: 25832312
Drug: CZP 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: CZP 400 mg every 4 weeks
Study: 30191421
Drug: CZP (combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: CZP (combined doses)
Study: 26915841
Drug: Early Steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early Steroid Withdrawal (ESW)
Study: 26915841
Drug: Control (steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (steroid treatment)
Study: 23990451
Drug: Aprepitant (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprepitant (80 mg)
Study: 16155825
Drug: Compound branch
Normalized name: Machilus thunbergii branch extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound branch chain amino acids injection (Aminic)
Study: 26188109
Drug: ONO-5334 (100mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONO-5334 (100mg slow-release tablets)
Study: 15460628
Drug: Caffeine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (400 mg at 7.5 h, 100 mg at 3 h, and 100 mg at 0 h)
Study: 8187119
Drug: Betaxolol 20
Normalized name: betaxolol 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betaxolol 20 mg/day (n = 54)
Study: 2976110
Drug: Atrial natriuretic
Normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrial natriuretic peptide (ANP) 150 μg over 30 minutes (protocol 1)
Study: 2976110
Drug: Atrial natriuretic
Normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrial natriuretic peptide (ANP) 200 μg over 30 minutes (protocol 2)
Study: 26232545
Drug: Inactivated whole‐cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated whole‐cell cholera vaccine (Shanchol), 2 doses
Study: 26232545
Drug: Inactivated whole‐cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated whole‐cell cholera vaccine (Shanchol), 1 dose
Study: 21458153
Drug: Udenafil 50mg
Normalized name: udenafil
DrugBank: Udenafil (DB06267)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Udenafil 50mg once daily for 12 weeks
Study: 21458153
Drug: Udenafil 75mg
Normalized name: udenafil
DrugBank: Udenafil (DB06267)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Udenafil 75mg once daily for 12 weeks
Study: 18972724
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy after electroacupuncture (EA)
Study: 18972724
Drug: Electroacupuncture (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture (EA) after exercise therapy
Study: 12955293
Drug: Scopolamine (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine (0.3 or 0.5 mg SC)
Study: 8222773
Drug: Tromantadine ointment
Normalized name: Tromantadine
DrugBank: Tromantadine (DB13288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tromantadine ointment 1%
Study: 8222773
Drug: Placebo (ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (ointment base alone)
Study: 31860981
Drug: Norepinephrine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine at 4 μg/minute
Study: 10227557
Drug: Continuous force
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous force application (100 g tipping force, elastics worn 24 hours per day)
Study: 10227557
Drug: Discontinuous force
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuous force application (100 g tipping force, elastics worn 12 hours per day)
Study: 8256911
Drug: Topical atropine
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical atropine (0.225 mg) given ipsilateral to UniCDA
Study: 8256911
Drug: Topical atropine
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical atropine given contralateral to UniCDA
Study: 8256911
Drug: Topical anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anesthesia with lidocaine given ipsilateral to UniCDA
Study: 8256911
Drug: Topical anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anesthesia with lidocaine
Study: 31581959
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplementation (1400 mg/day of EPA and DHA)
Study: 29644990
Drug: EMLA (anaesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMLA (anaesthetic cream)
Study: 24951881
Drug: Web-based methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Web-based methotrexate self-injection education video (12 minutes) followed by in-person nurse education
Study: 24951881
Drug: Web-based methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Web-based methotrexate self-injection education video
Study: 12504167
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of linoleic acid (15 g/day)
Study: 12504167
Drug: Intermediate dose
Normalized name: Prevotella intermedia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate dose of linoleic acid (7.5 g/day)
Study: 12504167
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (15 g palmitic acid/day)
Study: 10077397
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 (Q-Gel) 60 mg twice daily
Study: 10077397
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 (Q-Gel)
Study: 7655127
Drug: rhDNase 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhDNase 2.5 mg once daily
Study: 8756815
Drug: rhDNase 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhDNase 2.5 mg twice daily
Study: 2679960
Drug: Estradurin, 160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradurin, 160 mg per month
Study: 1255641
Drug: Intravenous 5%
Normalized name: immune globulin intravenous 5% intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 5% ethanol in 5% dextrose/water according to a weight‐time‐dose schedule
Study: 29050397
Drug: Lamotrigine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamotrigine (25 mg, 50 mg, 150 mg, 300 mg, once daily for 8 weeks)
Study: 29050397
Drug: Placebo (once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (once daily for 8 weeks)
Study: 20602263
Drug: Palonosetron 0.25
Normalized name: palonosetron 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palonosetron 0.25 mg intravenous
Study: 19485818
Drug: CRx-102 (combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRx-102 (combination of dipyridamole and prednisolone)
Study: 16401678
Drug: Behavioral family
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral family systems therapy for diabetes (BFST-D)
Study: 9261322
Drug: Topical 0.05%
Normalized name: ingenol topical 0.05% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.05% proparacaine
Study: 25369906
Drug: In-Home Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-Home Cognitive Behavioral Therapy (IH-CBT) plus home visiting
Study: 17962233
Drug: Anti-hypertensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-hypertensive treatment
Study: 21345781
Drug: Aspirin administration
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin administration (150 to 325 mg) within 6 hours postoperatively
Study: 21345781
Drug: Non-administration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-administration of aspirin
Study: 18492840
Drug: High protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High protein diet (1.4 g.kg(‐1).d(‐1) protein and 3 daily servings of dairy)
Study: 18492840
Drug: Conventional high-carbohydrate
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional high-carbohydrate diet (0.8 g.kg(‐1).d(‐1) protein and 2 daily servings of dairy)
Study: 17140522
Drug: Atraumatic restorative
Normalized name: DRESSING,RESTORE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atraumatic restorative treatment (ART) without local analgesia (LA)
Study: 14574650
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group received assessment, case management, and referral to appropriate resources.
Study: 14574650
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group (case management model).
Study: 11015798
Drug: Inactivated influenza
Normalized name: influenza, inactivated, whole virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated influenza vaccine administered to 60 children with 162 household contacts
Study: 11015798
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received hepatitis A vaccine administered to 67 age-matched children with 166 household contacts
Study: 9001837
Drug: Roxatidine 150
Normalized name: roxatidine 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxatidine 150 mg once nightly
Study: 9001837
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg once nightly
Study: 1293305
Drug: Amlodipine 5‐10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine 5‐10 mg once daily (n = 21)
Study: 1293305
Drug: Captopril 25‐50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 25‐50 mg twice daily (n = 20)
Study: 1293305
Drug: Amlodipine 5‐10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine 5‐10 mg once daily
Study: 1293305
Drug: Captopril 25‐50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 25‐50 mg twice daily
Study: 6336983
Drug: Intrapleural administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrapleural administration of 500 mg of tetracycline in solution (pH = 2.8)
Study: 6336983
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (solution of similar pH and appearance)
Study: 21532737
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose intravenous methylprednisolone (1 g) followed by oral prednisolone
Study: 7575052
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone alone
Study: 21532737
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (methylprednisolone + oral prednisolone and oral prednisolone alone)
Study: 16253403
Drug: Multi-fibre-enriched formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-fibre-enriched formula (15 g/l)
Study: 9495662
Drug: Captopril-based treatment
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril-based treatment
Study: 9495662
Drug: Conventional antihypertensive
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional antihypertensive therapy (diuretics and/or beta-blockers)
Study: 2939666
Drug: Inactivated influenza
Normalized name: influenza, inactivated, whole virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated influenza vaccine (A (H3N2) + A (H1N1), 3.0‐3.4 micrograms of hemagglutinin per 0.2 ml)
Study: 31133099
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (700 U) and 100 mg of calcium
Study: 31133099
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (100 U of Vitamin D and 100 mg of calcium)
Study: 19947273
Drug: Tuina treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tuina treatment on ten points using thumb and middle finger